Why might tirzepatide affect bones more than other GLP-1 drugs?

Tirzepatide also activates GIP receptors, unlike standard GLP-1 drugs. Rapid weight loss from the medication may also reduce bone density. Researchers are still investigating the exact mechanism.

Who should be most concerned about this finding?

People already at higher risk for osteoporosis — such as post-menopausal women, older adults, smokers, or those with low calcium intake — should discuss bone health monitoring with their doctor if they are taking tirzepatide.

What can I do to protect my bones while on tirzepatide?

Talk to your doctor about a bone density scan, ensure adequate calcium and vitamin D intake, do weight-bearing exercise, and avoid smoking and excess alcohol. These steps support bone health regardless of your medication.

Tirzepatide and Osteoporosis Risk vs Other GLP-1 Drugs

Key takeaways

✓Very large real-world study of nearly 460,000 patients provides meaningful signal
✓Propensity score matching helped balance patient groups for a fairer comparison
✓Findings highlight an important safety consideration for a widely prescribed medication

Quick specs

Journal	Diabetes research and clinical practice
Year	2025
PMID	41218687

What This Study Found

A large real-world study examined nearly 460,000 people with type 2 diabetes or obesity to see whether tirzepatide (Mounjaro/Zepbound) affects bone health differently than other GLP-1 receptor agonist medications.

The Key Finding

People who started tirzepatide had a 44% higher risk of developing osteoporosis or suffering a fragility fracture compared to those taking other GLP-1 medications such as semaglutide (Ozempic/Wegovy). They were also 61% more likely to be started on osteoporosis treatment.

Why This Matters

Tirzepatide works differently from standard GLP-1 drugs — it also activates GIP receptors. While this makes it very effective for blood sugar control and weight loss, this study suggests it may have an unintended effect on bone density. Rapid weight loss itself can reduce bone mass, which may partly explain the finding.

Important Caveats

This was a retrospective (looking back at records) observational study, so it cannot prove tirzepatide causes bone loss — only that there is an association. Other unmeasured factors could play a role. The follow-up period was only about 14 months.

What Should You Do?

If you are taking tirzepatide, do not stop your medication without speaking to your doctor. Discuss your bone health at your next appointment, especially if you are post-menopausal, older, or already at risk for osteoporosis. Your doctor may recommend a bone density scan or calcium and vitamin D supplementation.

References & Sources

Frequently asked questions

No. Do not stop any medication without talking to your doctor first. This study shows an association, not definite proof of harm. Your doctor can weigh the benefits and risks for your individual situation.

Editorial note

This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diabetes management. Last reviewed: July 16, 2026 by the MDS Diabetes editorial team.

What to do next

📚

Tirzepatide Linked to Higher Bone Loss Risk Than Other GLP-1 Drugs